Merck (MRK) Shares Up Significantly Since Jim Cramer Advised to “Stay the Course” [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
Merck & Co., Inc. (NYSE:MRK) aims to make an entry into the weight loss drug market through the HS-10535 drug, which it licensed from Hanosh Pharmaceutical through a $2 billion agreement. The shares are up by 33% over the past year and by 46% since Cramer discussed the firm on April 9th. Merck & Co., Inc. (NYSE:MRK)'s shares closed 3.8% higher on November 18th after data for its heart drug Winrevair. 2026 has been a good month for the stock as it is up by 12.4% year-to-date. Between February 2nd and February 6th, the shares gained 7.6%. On February 3rd, Merck & Co., Inc. (NYSE:MRK) reported its fiscal fourth quarter earnings report. The results saw the firm post $16.4 billion in revenue and $2.04 in adjusted profit per share to beat analyst estimates of $16.2 billion and $2.01. Additionally, Merck & Co., Inc. (NYSE:MRK) also revealed that it had expected to earn $65.5 billion to $67 billion in revenue, which sat below analyst estimates. The firm remarked that the loss of exclusivity
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Merck & Co., Inc. (MRK) had its "outperform" rating reaffirmed by Royal Bank Of Canada. They now have a $142.00 price target on the stock.MarketBeat
- Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins [Yahoo! Finance]Yahoo! Finance
- Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background StatinsBusiness Wire
- How Investors May Respond To Merck (MRK) WINREVAIR Phase 2 Success In Tough Heart Failure Segment [Yahoo! Finance]Yahoo! Finance
- Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 2/3/26 - Beat
MRK
Sec Filings
- 3/27/26 - Form SCHEDULE
- 3/12/26 - Form 3
- 2/24/26 - Form 10-K
- MRK's page on the SEC website